We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

98 hedge funds and large institutions have $1.4B invested in Theravance Biopharma in 2016 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 16 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 16

142% more call options, than puts

Call options by funds: $1.8M | Put options by funds: $744K

84.36% more ownership

Funds ownership: 0% → 84.36% (+84%)

10% more capital invested

Capital invested by funds: $1.27B → $1.4B (+$124M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

2% less funds holding

Funds holding: 100 → 98 (-2)

Holders
98
Holders Change
-2
Holders Change %
-2%
% of All Funds
2.45%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
22
Increased
42
Reduced
16
Closed
22
Calls
$1.8M
Puts
$744K
Net Calls
+$1.05M
Net Calls Change
+$1.75M

Top Buyers

Rank Fund Capital Flow
1
BG
Baupost Group
Massachusetts
+$59.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$47.7M
3
WIM
Woodford Investment Management
United Kingdom
+$34.1M
4
First Manhattan
First Manhattan
New York
+$24.7M
5
BFA
BlackRock Fund Advisors
California
+$12M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.92M
2
EI
EAM Investors
California
-$4.14M
3
PAM
Panagora Asset Management
Massachusetts
-$2.89M
4
CS
Credit Suisse
Switzerland
-$2.15M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$2.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.64M +$809K +26,088 +22%
BIM
27
BlackRock Investment Management
Delaware
$4.61M +$290K +9,354 +7%
TCIM
28
TIAA CREF Investment Management
New York
$4.32M +$406K +13,100 +11%
Morgan Stanley
29
Morgan Stanley
New York
$3.91M +$2.96M +95,272 +350%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$3.84M +$1.28M +41,132 +52%
Bank of America
31
Bank of America
North Carolina
$3.36M -$142K -4,568 -4%
RA
32
Royce & Associates
New York
$3.29M -$481K -15,500 -13%
JP Morgan Chase
33
JP Morgan Chase
New York
$2.9M +$1.47M +47,476 +109%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$2.8M -$183K -5,900 -6%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$2.64M +$183K +5,900 +8%
Deutsche Bank
36
Deutsche Bank
Germany
$2.51M +$954K +30,768 +64%
CS
37
Candriam SCA
Luxembourg
$2.39M +$2.33M +75,000 New
PAM
38
Panagora Asset Management
Massachusetts
$2.31M -$2.89M -93,014 -56%
TA
39
Teachers Advisors
New York
$2.22M +$347K +11,201 +19%
Swiss National Bank
40
Swiss National Bank
Switzerland
$2.02M +$233K +7,500 +13%
Goldman Sachs
41
Goldman Sachs
New York
$1.85M +$984K +31,736 +121%
AllianceBernstein
42
AllianceBernstein
Tennessee
$1.82M – – –
OWIM
43
Old West Investment Management
California
$1.66M +$197K +6,362 +14%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$1.58M +$1.54M +49,517 New
NSEDCP
45
NJ State Employees Deferred Compensation Plan
New Jersey
$1.57M – – –
CS
46
Credit Suisse
Switzerland
$1.5M -$2.15M -69,442 -60%
Allianz Asset Management
47
Allianz Asset Management
Germany
$1.48M – – –
Invesco
48
Invesco
Georgia
$1.38M -$1.45M -46,741 -52%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$1.3M +$131K +4,229 +12%
ProShare Advisors
50
ProShare Advisors
Maryland
$1.3M +$197K +6,366 +19%
1
2
3 4 5

TBPH Hedge Fund Activity: Q4 2016 in Review

98 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2016, worth a combined $1.4B — up 9.7% from $1.27B a quarter earlier.

Fund positioning in TBPH was balanced in Q4 2016: 22 funds opened new positions, 22 closed out, 42 added to existing stakes and 16 trimmed.

The largest buyer was Baupost Group, adding an estimated $59.6M. The largest seller was Wellington Management Group, exiting entirely with an estimated $6.92M sold.

  • 98 institutional investors held Theravance Biopharma (TBPH) as of Q4 2016, down from 100 in Q3 2016.
  • Funds reported $1.4B of Theravance Biopharma stock for Q4 2016, up 9.7% quarter-over-quarter.
  • 22 funds opened new Theravance Biopharma positions in Q4 2016 and 22 closed out, a net change of 0 holders.
  • The largest Theravance Biopharma buyer in Q4 2016 was Baupost Group, an estimated $59.6M added.
  • The largest Theravance Biopharma seller in Q4 2016 was Wellington Management Group, an estimated $6.92M sold.

Based on aggregated 13F filings for Q4 2016.